ACE and chronic kidney disease: SuPAR was evaluated in the two cohorts of CKD children: in the ESCAPE study (originally designed for assessment of blood pressure control and use of angiotensin-converting-enzyme inhibitors on CKD progression in pediatric patients) and the 4C trial (The Cardiovascular Comorbidity in Children with CKD).